Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR
2023; European Association of Percutaneous Cardiovascular Interventions; Volume: 19; Issue: 4 Linguagem: Inglês
10.4244/eij-d-23-00282
ISSN1969-6213
AutoresSusheel Kodali, Paul Sorajja, Christopher Meduri, Kari Feldt, João L. Cavalcante, Pankaj Garg, Nadira Hamid, Karl Poon, Magnus Settergren, Marcus Burns, Andreas Rück, Janarthanan Sathananthan, Alan Zajarías, Tamaz Shaburishvili, Teona Zirakashvili, Maia Zhividze, George Katchakhidze, Vinayak Bapat,
Tópico(s)Coronary Interventions and Diagnostics
ResumoTAVI is a widely accepted treatment for patients with severe aortic stenosis (AS). Despite the adoption of diverse therapies, opportunities remain to develop technologies tailored to provide optimal acute and potential long-term benefits, particularly around haemodynamics, flow and durability.
Referência(s)